Literature DB >> 8160778

Mice with hemangiomas induced by transgenic endothelial cells. A model for the Kasabach-Merritt syndrome.

N Dubois-Stringfellow1, L Kolpack-Martindale, V L Bautch, R G Azizkhan.   

Abstract

Inoculation of an established endothelial cell line from transgenic mouse hemangiomas (Py-4-1) into histocompatible mice induced vascular tumor formation at the site of infection with 100% frequency. Histological and hematological studies revealed that the mice developed hemangiomas with hematological changes similar to those found in the Kasabach-Merritt syndrome in humans, including hemolytic anemia and thrombocytopenic purpura. Modifications in the red blood cell count, hemoglobin concentration, hematocrit, and platelet count were directly correlated with the size of the hemangioma. Thus transgenic endothelial cell injection into histocompatible mice provides an in vivo model system to study the pathobiology of hemangiomas as well as the investigation of angiogenesis inhibitors.

Entities:  

Mesh:

Year:  1994        PMID: 8160778      PMCID: PMC1887230     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Long term follow-up of a case of Kasabach-Merritt syndrome successfully treated with radiotherapy and corticosteroids.

Authors:  J G Miller; C I Orton
Journal:  Br J Plast Surg       Date:  1992-10

2.  Kasabach-Merritt syndrome: treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy.

Authors:  B L Shulkin; L C Argenta; K J Cho; V P Castle
Journal:  J Pediatr       Date:  1990-11       Impact factor: 4.406

3.  Successful treatment of Kasabach-Merritt syndrome with pentoxifylline.

Authors:  Y de Prost; D Teillac; C Bodemer; O Enjolras; C Nihoul-Fekete; D de Prost
Journal:  J Am Acad Dermatol       Date:  1991-11       Impact factor: 11.527

4.  The Kasabach-Merritt syndrome: treatment with intermittent pneumatic compression.

Authors:  S E Aylett; A F Williams; D H Bevan; S J Holmes
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

Review 5.  Treatment of hemangiomatosis with recombinant interferon alfa.

Authors:  C W White
Journal:  Semin Hematol       Date:  1990-07       Impact factor: 3.851

6.  Morphological characterization of hemangiomatous tumors derived from a novel murine vascular endothelial cell line (F-2).

Authors:  K Tsujioka; K Toda; Y Maruguchi; Y Miyachi; S Imamura
Journal:  J Dermatol       Date:  1991-09       Impact factor: 4.005

7.  Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a.

Authors:  C W White; S J Wolf; D N Korones; H M Sondheimer; M F Tosi; A Yu
Journal:  J Pediatr       Date:  1991-01       Impact factor: 4.406

8.  Isolation and characterization of an established endothelial cell line from transgenic mouse hemangiomas.

Authors:  N A Dubois; L C Kolpack; R Wang; R G Azizkhan; V L Bautch
Journal:  Exp Cell Res       Date:  1991-10       Impact factor: 3.905

9.  Therapy of the Kasabach-Merritt syndrome with cryoprecipitate plus intra-arterial thrombin and aminocaproic acid.

Authors:  R L Stahl; J M Henderson; M A Hooks; L G Martin; A Duncan
Journal:  Am J Hematol       Date:  1991-04       Impact factor: 10.047

10.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

View more
  2 in total

1.  Induction of the angiogenic phenotype by Hox D3.

Authors:  N Boudreau; C Andrews; A Srebrow; A Ravanpay; D A Cheresh
Journal:  J Cell Biol       Date:  1997-10-06       Impact factor: 10.539

2.  Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system.

Authors:  K T Sabapathy; M S Pepper; F Kiefer; U Möhle-Steinlein; F Tacchini-Cottier; I Fetka; G Breier; W Risau; P Carmeliet; R Montesano; E F Wagner
Journal:  J Cell Biol       Date:  1997-05-19       Impact factor: 10.539

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.